Fig. 2From: Hepatitis B relapse after entecavir or tenofovir alafenamide cessation under anti-viral prophylaxis for cancer chemotherapyCumulative incidences of HBV relapse after cessation of antiviral prophylactic entecavir and TAF therapy in high-viremia group (HBV DNA > 2000 IU/mL) at initial treatment (A) virological and (B) clinical relapseBack to article page